Ultromics, a spinoff of the University of Oxford in the U.K. in collaboration with Mayo Clinic, has raised $55 million in series C funding to expand its heart failure detection platform, EchoGo, to U.S. hospitals.
EchoGo uses artificial intelligence to analyze routine heart ultrasound images and detect two difficult-to-diagnose conditions: HFpEF (heart failure with preserved ejection fraction) and cardiac amyloidosis. The tool is FDA cleared, Medicare reimbursed and requires no new equipment, according to a July 31 HIT Consultant report.
In studies, EchoGo improved HFpEF detection by 73.6% compared to traditional methods. Investors include London-based L&G and Lightrock; Palo Alto, Calif.-based Allegis Capital; Mountain View, Calif.-based Google Ventures; and University of Chicago Medicine.
